rabbit anti ythdf3 (Proteintech)
Structured Review
Rabbit Anti Ythdf3, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 151 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ythdf3+antibody/YTHDF3-specific+Antibody/pm42533115-85-81-85
Average 96 stars, based on 151 article reviews
Images
Related Articles
Magnetic Beads:Article Title: m 6 A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway Article Snippet: .. Then, protein A/G magnetic beads were incubated with control IgG antibody (30000, Proteintech), METTL3 antibody (15073, Proteintech), or Article Title: m <sup>6</sup> A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway Article Snippet: .. Then, protein A/G magnetic beads were incubated with control IgG antibody (30000, Proteintech), METTL3 antibody (15073, Proteintech), or Article Title: Methyltransferase-like 3-catalysed N6-methyladenosine methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. Article Snippet: 3 Aims: Vascular smooth muscle cells (VSMCs) are involved in the etiology of atherosclerosis, but whether 4 methyltransferase-like 3 (METTL3)-catalyzed N-methyladenosine (mA) modulates the contribution of 5 VSMCs to atherosclerosis remains elusive.. 6 Methods and Results: We generated tamoxifen-inducible VSMC-specific METTL3 knockout mice with 7 VSMC lineage tracing, and found that VSMC-specific METTL3 deficiency substantially attenuated 8 atherosclerosis and reduced the proportion of VSMCs in plaques, due to the inhibition of VSMC 9 atheroprone phenotype as characterized by macrophage-like and inflammatory features as well as high 10 migratory and proliferative capacity. mA-methylated RNA immunoprecipitation sequencing (MeRIP-Seq) 11 combined with polysome profiling analysis mechanistically displayed METTL3 catalyzed mA methylation 12 of myocardin-related transcription factor A (MRTFA) mRNA, and further enhanced YTH N13 methyladenosine RNA binding protein F3 (YTHDF3)-dependent MRTFA mRNA translation.. Conversely, 14 adenovirus or adeno-associated virus-mediated VSMC-specific MRTFA overexpression abolished 15 METTL3 deficiency-mediated alleviation of VSMC atheroprone phenotypic switching and atherosclerotic 16 progression both in vitro and in vivo. Incubation:Article Title: m 6 A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway Article Snippet: .. Then, protein A/G magnetic beads were incubated with control IgG antibody (30000, Proteintech), METTL3 antibody (15073, Proteintech), or Article Title: m <sup>6</sup> A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway Article Snippet: .. Then, protein A/G magnetic beads were incubated with control IgG antibody (30000, Proteintech), METTL3 antibody (15073, Proteintech), or Article Title: YTHDF3 promotes the progression of gastric cancer by activating Wnt/β-catenin signaling pathway via targeting NEK7 Article Snippet: The cells were gently washed three times with PBS once the cell fusion rate had reached 20–30%.The cells were then blocked with 2% bovine serum albumin (BSA-V; Solarbio; Catalog number: A8020), fixed with 4% paraformaldehyde, and penetrated with 0.2% Triton X-10 (Solarbio; Catalog number: T8200). .. Control:Article Title: m 6 A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway Article Snippet: .. Then, protein A/G magnetic beads were incubated with control IgG antibody (30000, Proteintech), METTL3 antibody (15073, Proteintech), or Article Title: m <sup>6</sup> A Modification of Profilin-1 in Vascular Smooth Muscle Cells Drives Phenotype Switching and Neointimal Hyperplasia via Activation of the p-ANXA2/STAT3 Pathway Article Snippet: .. Then, protein A/G magnetic beads were incubated with control IgG antibody (30000, Proteintech), METTL3 antibody (15073, Proteintech), or Lysis:Article Title: YTHDF3 promotes the progression of gastric cancer by activating Wnt/β-catenin signaling pathway via targeting NEK7 Article Snippet: Following the instructions in the PierceTM Classic Magnetic IP/Co-IP Kit (Thermo Scientific, Waltham, USA; Catalog number: 88804), cell lysis was then carried out. .. After lysis, the cell lysate was mixed with 10 μg of the FLAG-tag:Article Title: SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis. Article Snippet: .. The following antibodies were used in this study: β-actin antibody (TA-09, Zsbio), β-tubulin antibody (TA-10, Zsbio), SUMO1 antibody (ET1606-53, Huabio), UBC9 antibody (ET1610-21, Huabio), SENP1 antibody (ET7108-53, Huabio), YBX1 antibody (ET1609-10, Huabio), DDX5 antibody (ET1705-32, Huabio), HNRPU antibody (ET7107-10, Huabio), G3BP1 antibody (HA721314, Huabio), ENOA antibody (ET1705-56, Huabio), FLAG-tag antibody (0912-1 or HA601080, Huabio), Myc-tag antibody (EM31105, Huabio), HA-tag antibody (ET1611-49, Huabio), Lamin B1 antibody (ET1606-27, Huabio), His-tag antibody (66005-1-Ig, Proteintech), IGF2BP1 antibody (22803-1-AP, Proteintech), IGF2BP2 antibody (11601-1-AP, Proteintech), IGF2BP3 antibody (14642-1-AP, Proteintech), Article Title: SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis Article Snippet: .. The following antibodies were used in this study: β-actin antibody (TA-09, Zsbio), β-tubulin antibody (TA-10, Zsbio), SUMO1 antibody (ET1606-53, Huabio), UBC9 antibody (ET1610-21, Huabio), SENP1 antibody (ET7108-53, Huabio), YBX1 antibody (ET1609-10, Huabio), DDX5 antibody (ET1705-32, Huabio), HNRPU antibody (ET7107-10, Huabio), G3BP1 antibody (HA721314, Huabio), ENOA antibody (ET1705-56, Huabio), FLAG-tag antibody (0912-1 or HA601080 , Huabio), Myc-tag antibody (EM31105, Huabio), HA-tag antibody (ET1611-49, Huabio), Lamin B1 antibody (ET1606-27, Huabio), His-tag antibody (66005-1-Ig, Proteintech), IGF2BP1 antibody (22803-1-AP, Proteintech), IGF2BP2 antibody (11601-1-AP, Proteintech), IGF2BP3 antibody (14642-1-AP, Proteintech), Immunoprecipitation:Article Title: Methyltransferase-like 3-catalysed N6-methyladenosine methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. Article Snippet: 3 Aims: Vascular smooth muscle cells (VSMCs) are involved in the etiology of atherosclerosis, but whether 4 methyltransferase-like 3 (METTL3)-catalyzed N-methyladenosine (mA) modulates the contribution of 5 VSMCs to atherosclerosis remains elusive.. 6 Methods and Results: We generated tamoxifen-inducible VSMC-specific METTL3 knockout mice with 7 VSMC lineage tracing, and found that VSMC-specific METTL3 deficiency substantially attenuated 8 atherosclerosis and reduced the proportion of VSMCs in plaques, due to the inhibition of VSMC 9 atheroprone phenotype as characterized by macrophage-like and inflammatory features as well as high 10 migratory and proliferative capacity. mA-methylated RNA immunoprecipitation sequencing (MeRIP-Seq) 11 combined with polysome profiling analysis mechanistically displayed METTL3 catalyzed mA methylation 12 of myocardin-related transcription factor A (MRTFA) mRNA, and further enhanced YTH N13 methyladenosine RNA binding protein F3 (YTHDF3)-dependent MRTFA mRNA translation.. Conversely, 14 adenovirus or adeno-associated virus-mediated VSMC-specific MRTFA overexpression abolished 15 METTL3 deficiency-mediated alleviation of VSMC atheroprone phenotypic switching and atherosclerotic 16 progression both in vitro and in vivo. |

![a An experimental design of the present study. Responders (tumor regression grade [TRG] scores of 0–1 or patients who achieved clinical complete or partial response; n = 6) and non-responders (TRG scores of 2–3 or patients who achieved clinical minimal response; n = 8). Created in BioRender. GU, T. (2025) https://BioRender.com/ppcp3bu . b Transcriptomic data from clinical samples (Cohort 1) were subjected to GO enrichment analysis to determine alterations in biological processes, molecular functions, and cellular components. Data are visualized in the provided bubble diagram. c Bubble diagram visualizing the alteration of m 6 A regulators in clinical ESCC sample Cohort 1. d GO enrichment analysis of differentially expressed proteins between shYTHDF3 and Mock cells. The Rich Factor represents the ratio of enriched genes; bubble size denotes gene count, and color indicates -log₁₀P value. Statistical significance was calculated using a two-sided Fisher’s exact test with Benjamini–Hochberg FDR correction. e Rank-based gene set enrichment analysis (GSEA) of signaling pathway alterations and representative protein changes in shYTHDF3 cells. Terms in red represent the primary targets. f Representative immunohistochemical staining images of INCENP, CDCA8, and <t>YTHDF3</t> in ESCC Cohort 1 tissue samples from the indicated responders and non-responders. Scale bar = 250 μm. g INCENP, CDCA8, and YTHDF3 score levels were measured in tissue derived from ESCC Cohort 1 samples. Responders (TRG1, n = 4) and non-responders (TRG 2-3, n = 8). h Correlation between YTHDF3 protein scores and INCENP or CDCA8 protein scores in Cohort 1. Correlation coefficients (R) and P values were determined using a two-sided Pearson correlation test. Shaded areas represent the 95% confidence interval of the regression line. i Representative radiological images and INCENP, CDCA8 IHC-stained tissues (scale bar = 250 μm) in Cohort 2, ESCC patients with favorable and unfavorable responses to NACT [responders (TRG 0–1, n = 31) and non-responders (TRG 2–3, n = 37)]. Red arrows represent the lesion sites. j Immunohistochemical analysis of INCENP and CDCA8 scores in ESCC tissues from Cohort 2, including responders (TRG 1, n = 10) and non-responders (TRG 2-3, n = 37). k Stacked bar plots showing distributions of clinical outcomes (death, n = 10, progression, n = 10, remission, n = 10) in patients with low and high expression of INCENP and CDCA8. Statistical significance was assessed using a two-sided Chi-square test. Data were presented as means ± SD. P -values were determined by a two-tailed unpaired t-test ( g , j ). Source data are provided as a file.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9975/pmc12909975/pmc12909975__41467_2026_68371_Fig1_HTML.jpg)